CHMP approves 11 new drugs, rejects one
Several drugs from Danish developers have been appraised positively by the EMA's expert committee, the CHMP, during its November meeting. In total, 11 drugs have gone through the eye of the needle.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Novo Nordisk, Lundbeck and Ascendis Pharma count among the companies that have cause for celebration after this month's meeting at the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP recommends higher dose of Novo Nordisk's Ozempic
For subscribers
.jpg&w=384&q=75)
